Research programme: skin disorder therapeutics - Dermira

Drug Profile

Research programme: skin disorder therapeutics - Dermira

Alternative Names: QLT-450; VAL-003

Latest Information Update: 30 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator QLT
  • Developer Dermira
  • Class Small molecules
  • Mechanism of Action Enzyme inhibitors; Immunomodulators; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acne; Atopic dermatitis; Vitiligo

Most Recent Events

  • 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
  • 10 Sep 2013 Preclinical development is ongoing in USA
  • 20 Oct 2011 Dermira acquires Valocor Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top